News + Font Resize -

Oasmia Pharma enrolls first patient in phase I study of anti-cancer drug, Docecal
Uppsala, Sweden | Saturday, April 2, 2016, 17:00 Hrs  [IST]

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, announced that the first patient has been enrolled in the phase I clinical study of the company’s next-generation cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015.

Docecal is a nanoparticle and water-soluble formulation of docetaxel, one of the most commonly used anti-cancer substances in oncology today, in combination with the company’s patented technology XR17. A standard treatment for multiple cancers including prostate, breast, lung and stomach, docetaxel is the most active substance in the cytostatic Taxotere, marketed by the global healthcare provider Sanofi-Aventis. Prior to the patent expiration in 2010, Sanofi-Aventis executed $3 billion in Taxotere sales 2009. Taxotere has continued to perform well.

Docecal is a water soluble formulation of docetaxel in combination with Oasmia’s patented technology XR17. Docetaxel is standard treatment for a variety of different kinds of cancers, such as prostate cancer, breast cancer, lung cancer and stomach cancer.

Post Your Comment

 

Enquiry Form